Pharma 2020 program supported more than 400 drug development projects

Speaking at the 8th All-Russian Congress of Patients, Sergey Tsyb, the Deputy Minister of Industry and Trade of the Russian Federation, noted the constructive dialog between the Ministry of Industry and Trade, Russian Union of Patients and patient organizations in the country.

The Deputy Minister emphasized that, today, a comprehensive patient care is impossible without proper provision of high quality and effective drugs, medical devices and equipment.

“Over the past five years, the program for the development of pharmaceutical and medical industry allowed us to witness the active expansion of capabilities by the Russian manufacturers and growing share of Russian medicines in the Russian pharmaceutical market,” said Sergey Tsyb. “In 2017, for the first time, we surpassed the 30% share threshold in monetary terms, thus, demonstrating that the companies learned how to manufacture the medicinal products of any complexity. In 4 years, 19 new plants were built based on most advanced international standards. In the period of the program implementation, the support was provided to more than 400 projects to create new medicines and molecules, and more than 100 of them are at the stage of clinical trials.”

Currently, the Russian Ministry of Industry and Trade is actively working on creating a whole range of new drugs in the area of pulmonology. According to the Deputy Minister, these activities are supported by major medical institutions. Recently, Russian companies developed a new drug for the treatment of Hepatitis C and diabetes mellitus type 2. In the segment of 7 Nosologies, the Russian manufacturers have increased their share from 4% to 40%. Over 5 years, the production of Russian-made drugs for the treatment of oncological diseases showed a three-fold increase.

Speaking at the 8th All-Russian Congress of Patients, Sergey Tsyb, the Deputy Minister of Industry and Trade of the Russian Federation, noted the constructive dialog between the Ministry of Industry and Trade, Russian Union of Patients and patient organizations in the country.

“Over the past five years, the program for the development of pharmaceutical and medical industry allowed us to witness the active expansion of capabilities by the Russian manufacturers and growing share of Russian medicines in the Russian pharmaceutical market,” said Sergey Tsyb. “In 2017, for the first time, we surpassed the 30% share threshold in monetary terms, thus, demonstrating that the companies learned how to manufacture the medicinal products of any complexity. In 4 years, 19 new plants were built based on most advanced international standards. In the period of the program implementation, the support was provided to more than 400 projects to create new medicines and molecules, and more than 100 of them are at the stage of clinical trials.”

Currently, the Russian Ministry of Industry and Trade is actively working on creating a whole range of new drugs in the area of pulmonology. According to the Deputy Minister, these activities are supported by major medical institutions. Recently, Russian companies developed a new drug for the treatment of Hepatitis C and diabetes mellitus type 2. In the segment of 7 Nosologies, the Russian manufacturers have increased their share from 4% to 40%. Over 5 years, the production of Russian-made drugs for the treatment of oncological diseases showed a three-fold increase.